Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies
- PMID: 36756502
- PMCID: PMC9890594
- DOI: 10.1039/d2na00483f
Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies
Abstract
Background: Leukemia is a malignant disease that threatens human health and life. Nano-delivery systems improve drug solubility, bioavailability, and blood circulation time, and release drugs selectively at desired sites using targeting or sensing strategies. As drug carriers, they could improve therapeutic outcomes while reducing systemic toxicity. They have also shown promise in improving leukemia detection and diagnosis. The study aimed to assess the potential of nanotechnology-based diagnostics and therapeutics in preclinical human acute lymphoblastic leukemia (h-ALL). Methods: We performed a systematic search through April 2022. Articles written in English reporting the toxicity, efficacy, and safety of nanotechnology-based drugs (in the aspect of treatment) and specificity, limit of detection (LOD), or sensitivity (in the aspect of the detection field) in preclinical h-ALL were included. The study was performed according to PRISMA instructions. The methodological quality was assessed using the QualSyst tool. Results: A total of 63 original articles evaluating nanotechnology-based therapeutics and 35 original studies evaluating nanotechnology-based diagnostics were included in this review. As therapeutics in ALL, nanomaterials offer controlled release, targeting or sensing ligands, targeted gene therapy, photodynamic therapy and photothermic therapy, and reversal of multidrug-resistant ALL. A narrative synthesis of studies revealed that nanoparticles improve the ratio of efficacy to the toxicity of anti-leukemic drugs. They have also been developed as a vehicle for biomolecules (such as antibodies) that can help detect and monitor leukemic biomarkers. Therefore, nanomaterials can help with early diagnostics and personalized treatment of ALL. Conclusion: This review discussed nanotechnology-based preclinical strategies to achieve ALL diagnosis and therapy advancement. This involves modern drug delivery apparatuses and detection devices for prompt and targeted disease diagnostics. Nonetheless, we are yet in the experimental phase and investigational stage in the field of nanomedicine, with many features remained to be discovered as well as numerous problems to be solved.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures



Similar articles
-
Nanotechnology: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1. Ont Health Technol Assess Ser. 2006. PMID: 23074489 Free PMC article.
-
Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy.Curr Drug Metab. 2019;20(6):416-429. doi: 10.2174/1389200219666180918111528. Curr Drug Metab. 2019. PMID: 30227814 Review.
-
Engineered Hybrid Nanoparticles for On-Demand Diagnostics and Therapeutics.Acc Chem Res. 2015 Dec 15;48(12):3016-25. doi: 10.1021/acs.accounts.5b00316. Epub 2015 Nov 25. Acc Chem Res. 2015. PMID: 26605438
-
Harnessing nanotechnology for cancer treatment.Front Bioeng Biotechnol. 2025 Jan 20;12:1514890. doi: 10.3389/fbioe.2024.1514890. eCollection 2024. Front Bioeng Biotechnol. 2025. PMID: 39902172 Free PMC article. Review.
-
Nanotechnology-based biomedical devices in the cancer diagnostics and therapy.Med Oncol. 2025 Jan 20;42(2):50. doi: 10.1007/s12032-025-02602-x. Med Oncol. 2025. PMID: 39828813 Review.
Cited by
-
Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery.Biomater Res. 2023 May 6;27(1):42. doi: 10.1186/s40824-023-00365-y. Biomater Res. 2023. PMID: 37149607 Free PMC article. Review.
-
A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases.Int J Mol Sci. 2023 Nov 8;24(22):16098. doi: 10.3390/ijms242216098. Int J Mol Sci. 2023. PMID: 38003288 Free PMC article. Review.
-
Folic Acid-Decorated Chitosan-PLGA Nanobiopolymers for Targeted Drug Delivery to Acute Lymphoblastic Leukemia Cells: In Vitro Studies.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241308077. doi: 10.1177/15330338241308077. Technol Cancer Res Treat. 2024. PMID: 39711084 Free PMC article.
-
Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials.Eur J Med Res. 2023 Dec 5;28(1):566. doi: 10.1186/s40001-023-01539-z. Eur J Med Res. 2023. PMID: 38053150 Free PMC article. Review.
-
Targeted therapy for leukemia based on nanomaterials.Heliyon. 2024 Jul 21;10(15):e34951. doi: 10.1016/j.heliyon.2024.e34951. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39144922 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous